Purpose. To evaluate the downstaging efficacy of yttrium-90 radioembolization (Ytt-90)-associated with chemotherapy and the results of surgery for initially unresectable huge intrahepatic cholangiocarcinoma (ICC). Methods. Between January 2008 and October 2013, unresectable ICC were treated with chemotherapy and Ytt-90. Patients with unique tumors localized to noncirrhotic livers and without extrahepatic metastasis were considered to be potentially resectable and were evaluated every 2 months for possible secondary resection. Results. Forty-five patients were treated for unresectable ICCs; ten had potentially resectable tumors, and eight underwent surgery. Initial unresectability was due to the involvement of the hepatic veins or portal vein of the future liver remnant in seven and one cases, respectively. Preoperative treatment induced significant decreases in tumor volume (295 vs. 168 ml, p = 0.02) and allowed for R0 resection in all cases. Three patients (37.5 %) had ClavienDindo grade three or higher complications, including two postoperative deaths. The median follow-ups were 15.6 [range 4-40.7] months after medical treatment initiation and 7.2 [0.13-36.4] months after surgery. At the end of the study period, five patients were still alive, with one patient still alive 40 months after medical treatment initiation (36.4 months after surgery); two patients experienced recurrences. Conclusions. For initially unresectable huge ICCs, chemotherapy with Ytt-90 radioembolization is an effective downstaging method that allows for secondary resectability.
Results. Forty-five patients were treated for unresectable ICCs; ten had potentially resectable tumors, and eight underwent surgery. Initial unresectability was due to the involvement of the hepatic veins or portal vein of the future liver remnant in seven and one cases, respectively. Preoperative treatment induced significant decreases in tumor volume (295 vs. 168 ml, p = 0.02) and allowed for R0 resection in all cases. Three patients (37.5 %) had ClavienDindo grade three or higher complications, including two postoperative deaths. The median follow-ups were 15.6 [range 4-40.7 ] months after medical treatment initiation and 7.2 [0. 13-36.4 ] months after surgery. At the end of the study period, five patients were still alive, with one patient still alive 40 months after medical treatment initiation (36.4 months after surgery); two patients experienced recurrences. Conclusions. For initially unresectable huge ICCs, chemotherapy with Ytt-90 radioembolization is an effective downstaging method that allows for secondary resectability.
Although rare, intrahepatic cholangiocarcinomas (ICC) are the second most frequent primary liver cancer after hepatocellular carcinomas (HCC).
1,2 ICC account for 5-10 % of primary liver malignancies, and their incidence has significantly increased over the last two decades. 1, [3] [4] [5] Complete surgical resection remains the only potentially curative treatment. 6, 7 However, because these tumors remain clinically silent, patients are generally diagnosed when the tumors are huge. Resection is therefore frequently impossible or incomplete, and recurrence rates remain high. [7] [8] [9] [10] For patients with huge ICC, nonresectability results from the vascular involvement (i.e., glissonian vessels and hepatic veins) of the potential future liver remnant (FLR). In these patients, tumor downsizing can improve the resectability and eventually lead to curative treatment, regardless of the method used to achieve downsizing. Currently, no preoperative treatment has proven to be efficient in this setting.
Radioembolization using yttrium-90 (Ytt-90) has demonstrated its efficacy in the palliative treatment of HCC and ICC. [11] [12] [13] [14] [15] [16] Our team has previously reported that, in HCC patients, Ytt-90 radioembolization is effective in reducing tumor volumes and simultaneously inducing hypertrophy of the liver contralateral to the tumor. 17 This combined effect might allow for secondary resection in patients who are initially unresectable. The aim of this study was to report our experience with initially unresectable patients with huge ICC who were first treated with a combination of intra-arterial Ytt-90 radioembolization and systemic chemotherapy and subsequently became secondarily resectable.
PATIENTS AND METHODS

Patients
Between January 2008 and October 2013, all patients with mass-forming type ICC judged to be unresectable by a multidisciplinary committee including oncologists, radiologists, and senior surgeons were offered a combination of intra-arterial Ytt-90 radioembolization and systemic chemotherapy as a palliative treatment. The inclusion criteria were a biopsy-proven ICC, an Eastern Cooperation Oncology Group performance status of two or less, and adequate liver function (i.e., normal bilirubin blood level). 18 The treated patients were closely monitored with physical examinations, biology tests, evaluations of the adverse effects after each chemotherapy cycle, and computed tomographic (CT) scans every 2 months.
This retrospective study received approval from the local ethical committee (authorization number 14.28).
Chemotherapy and Ytt-90 Radioembolization
Systemic chemotherapy was first initiated using gemcitabine and/or platinum salts. Gemcitabine was not administered in the cycles before and after each radioembolization to avoid possible increases in toxicity.
The Ytt-90 radioembolizations were administered few weeks after the initiation of the chemotherapy as previously described. 17 Briefly, a supraselective diagnostic angiography with 99m Tc macroaggregated albumin was first performed to evaluate pulmonary shunting and the absence of digestive uptake and to calculate the Ytt-90 activity according to target volume. Therapeutic arteriography was performed 8 days later using glass microspheres (TheraSphere). When necessary, a second injection was administered 1 month later to treat the entire tumor. Chemotherapy was pursued after radioembolization.
Tumor Response and Resectability Criteria
All patients underwent CT scan before the initiation of chemotherapy and every 2 months thereafter with evaluation of the tumor responses by the multidisciplinary committee. Patients with solitary tumors on noncirrhotic livers and an absence of extrahepatic metastases were considered for potential resection. Resectability was defined as the possible complete removal of the tumor regardless of the margin width, regardless of the technique (i.e., in situ or ex vivo resections) and with the use of complex vascular reconstruction when necessary. When tumor resectability was possible in terms of the anatomical criteria (judged on CT scan and liver magnetic resonance imaging), but the future liver remnant volume (FLRV) represented less than 30 % of the total liver volume (TLV), additional portal vein embolization (PVE) was performed. The liver resections included hilar lymphadenectomy in all cases. The extrahepatic bile duct was resected when necessary, and bilioenteric anastomosis using a Roux-en-Y was performed. The time between the last chemotherapy cycle and the surgery was at least 1 month.
Survival Analyses
Overall survival was calculated from the time of the initiation of chemotherapy and from the time of surgery.
Disease-free survival was calculated from time of surgery.
Statistical Analyses
The quantitative variables are expressed as the medians with ranges. Categorical variables are expressed as numbers and percentages. Volumetric values were compared with paired Wilcoxon tests.
Survival analyses were performed by the Kaplan-Meier method. Statistical analyses were performed with R statistical software, version 3.0.0. Volumetric analyses were performed by Myrian Xp liver software. Differences were considered significant when p \ 0.05.
RESULTS
During the study period, 54 patients underwent liver resection for ICC without any preoperative treatment, and 45 patients were treated with a combination of systemic chemotherapy and intra-arterial Ytt-90 radioembolization for unresectable ICCs. Twenty-seven patients (60 %) had multiple lesions and/or extrahepatic disease and were treated with palliative intent. Four patients (9 %) were treated for tumor recurrence. Among the 14 patients (31 %) remaining, four had liver cirrhosis with portal hypertension. Eventually, ten patients had single huge ICCs that developed in noncirrhotic liver without extrahepatic disease and were considered for potential resection. Ultimately, eight patients (five women and three men) underwent surgical resection with curative intent and represent our study population. The two remaining patients were not resected as a result of tumor progression (Fig. 1 ).
Among these eight resected patients, the initial unresectabilities were due to tumoral involvement of the hepatic veins of the FLR in seven cases and tumoral involvement of the portal pedicle of the FLR in the remaining case. The demographic data and tumor characteristics of the resected patients are reported in Table 1 .
Preoperative Treatment
All eight patients received a median of seven [range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] cycles of systemic chemotherapy. Chemotherapy associated gemcitabine (6 cases) or 5-fluorouracil (2 cases) with a platinum salts (oxaliplatin in five cases, and cisplatin in three cases).
Intra-arterial Ytt-90 was administered with a median injected activity of 2 [1.5-3.2] GBq. Two patients underwent two successive radioembolization procedures in order to treat the entire tumor volume. The median duration of chemoradioembolization therapy (i.e., the time from the initiation of chemotherapy until surgery) was 7.6 [3. 4-16.7] months. Tolerance was excellent, and no patient presented grade III or higher toxicity.
Tumor Downstaging and FLRV Hypertrophy
There was no difference between the pre-and posttreatment median TLVs There was no significant difference between the preand posttreatment median FLRVs [467 (185-917) ml vs. 507.5 (310-795) ml, respectively; p = 0.46], while the median FLRV/TLV ratio significantly increased (27.2 vs. 35.9 %, p = 0.04) and was greater than 30 % in seven cases [30.0-49.7 %]. The remaining patient had a pretreatment FLRV/TLV ratio of 23.8 %, which reached 38.5 % after PVE.
Because of tumor shrinkage, the hepatic vein of the FLR was distant from the tumor in 6 cases (from the seven initially invaded), and the portal pedicle was distant from the tumor in the last case. In one case, the hepatic vein of the FLR had still closed contact with the tumor and required ex vivo surgery with retrohepatic vena cava replacement and hepatic vein reconstruction. 
Surgical Procedure
The resections were performed in situ with the exception of one patient who underwent an ex vivo surgery because complex vascular reconstruction was required. Extended hepatectomies (i.e., resection of at least five segments) were performed in all cases, including right hepatectomies extended to segment one in two cases (25 %), right trisectionectomy extended to segment one in five cases (62.5 %), and a left trisectionectomy in one case (12.5 %). 19 The biliary confluence and the extrahepatic biliary tree were resected in two cases with bilioenteric reconstruction. The retrohepatic inferior vena cava was resected in four cases (laterally in two cases and totally in two cases with vascular prosthetic replacement). The median duration of surgery was 210 [150-600] min. All in situ resections were performed under continuous simultaneous clamping of the portal pedicle and the infrahepatic inferior vena cava. Three patients (37.5 %) required blood transfusion.
R0 resection was achieved in all patients.
Postoperative Course
Three patients (37.5 %) experienced Clavien-Dindo complication of grade three or more during their hospital stays. Among these three patients, two died. One patient had a sudden massive stroke on postoperative day 9 (1 day before planned discharge). Urgent laparotomy was made in order to eliminate abdominal sepsis but did not find any abdominal complication. The second patient had undergone an ex vivo resection of the tumor with arterial, portal, and suprahepatic vein reconstructions and developed severe liver failure due to thrombosis of both the hepatic artery and portal vein. Urgent liver revascularization did not prevent the fatal evolution at postoperative day 4 ( Table 2) .
None of the remaining patients exhibited bile leakage or postoperative hemorrhage. The median hospital stay duration was 9.5 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] days.
Midterm Evolution and Survival Analysis
The median follow-up time for the entire series was 15.6 [4-40.7] months from the initiation of medical treatment and 7.2 [0. 13-36.4 ] months from the date of surgery.
Among the six patients who survived the postoperative period, one patient (aged 80 years) died 6.5 months after surgery (14 months after the initiation of treatment) without evidence of initial disease recurrence, and five patients were still alive (Fig. 3) . The median follow-up for these six patients was 16.9 [15.2-40.7] months after the initiation of medical treatment [8.2 (2-36.4) months after surgery].
Two patients experienced recurrences. One patient exhibited lung metastasis 19 months after surgery and received chemotherapy and stereotaxic radiotherapy and is still alive 36.4 months after the surgery (40.7 months after medical treatment initiation). The other patient exhibited multiple-site metastases (lung, liver, and liver hilum lymph nodes) 7 months after surgery (15.1 months after the initiation of medical treatment). The median disease-free survival was 19.1 months when considering recurrence only.
DISCUSSION
ICC is a primary liver tumor whose incidence and mortality are increasing in Western countries. 5 Complete surgical resection is the only available treatment that allows for prolonged survival. For patients with unresectable disease, survival without treatment is less than a year. 20 Because the lesion remains clinically silent, ICCs are generally diagnosed at an advanced stage, and only a minority of patients have resectable disease. Indeed, Tan et al. reported a global resection rate of 12 %, with only 37 % of patients with potentially resectable disease (defined by single unilobar tumors without evidence of vascular invasion) eventually undergoing resection. 7 In the present study, of the 10 patients who were eligible for surgery, eight patients (80 %) with single localized ICCs who were initially considered to have unresectable disease were offered a complete resection after the induction treatment of combined chemotherapy and Ytt-90 radioembolization.
For unresectable ICCs, systemic chemotherapy (associating gemcitabine and platinum salt) produces a response rate of 20-35 % and a median overall survival of 10-15 months. [21] [22] [23] [24] [25] Such low efficiency is also associated with a high rate of grade 3-4 toxicity. 21 Ytt-90 radioembolization is a novel and promising therapy for the palliative treatment of ICC, and to our knowledge, five studies (two from the same team) have reported median overall survivals of 9.3-22 months after treatment. [13] [14] [15] [16] 26 In a study by Ibrahim et al., one patient was downstaged to resection, and another patient was downstaged to liver transplantation. 13 This study was expanded to 46 patients, and 3 additional patients eventually underwent resection or transplantation. 16 Saxena et al. also reported 1 patient who was downstaged to surgery.
14 Reported tolerances of Ytt-90 radioembolization were excellent, and usually better than other intra-arterial treatment. 27, 28 In our study, no patients presented severe toxicity (grade III or higher), and particularly no liver adverse effect. Moreover, because postoperative morbidity was low (i.e., no biliary leakage nor postoperative hemorrhage), we consider Ytt-90 radioembolization to be a suitable preoperative treatment that seems to avoid damage to liver parenchyma and biliary structures even after more than one procedure.
Recently, Servajean et al. reported a case of a huge ICC with involvement of the three hepatic veins that was initially nonresectable. 29 After Ytt-90 radioembolization with resin microspheres (SIRS-spheres) combined with chemotherapy (eight cycles before and four cycles after radioembolization), the patient underwent a left extended hepatectomy with R0 resection. More recently, Henry et al. reported a series of nine patients who underwent resection after preoperative radioembolization. 30 Most of patients had colorectal or neuroendocrine liver metastases, with two patients converted from initially unresectable to resectable status.
In our study, eight of ten patients eventually underwent resection. This high percentage compared to published results might have been because only solitary tumors and noncirrhotic livers were considered for surgery. Indeed, we did not offer extended liver resection to patients with cirrhotic liver even when the FLRV was greater than 30 % or liver transplantation because of poor outcomes. 31 Although preoperative treatment induced significant tumor volume reductions, R0 resection could only be achieved through extended hepatectomy with the removal of at least five segments in all cases, and half of the patients also had complex vascular reconstructions (including inferior vena cava resection in four cases and ex vivo surgery in one case). These factors might explain our postoperative mortality rate. However, the mortality rate should be interpreted in light of the homogram of Wang et al., which predicts 3-year survival rates below \15 % among patients with similar huge ICCs with vascular involvements. 32 Moreover, it should be noted that one of the two postoperative deaths was not related to the surgery.
Although our mortality rate seemed to be high, it is consistent with previous published data. Indeed, Henry et al. found a 30-day mortality rate of 33 % in their series. 30 Even if patients in these series cannot be compared with ours, this fact should motivate clinicians to carefully select candidates who will benefit from surgery after preoperative treatment.
After complete resection, ICC's recurrence rate remained high, and recurrence typically occurred within the first year after surgery. 8, 33 In our series, two of the six patients who were alive after the postoperative course exhibited recurrence (at 19 and 7 month after surgery), but no deaths related to tumor recurrence were observed. These patients may have benefit from a more extensive radiologic assessment before surgery, including FDG PET-CT, in order to detect potential occult metastatic sites not seen on conventional imaging. 34, 35 Because of our study's small population size, no predictive factor of recurrence or mortality could be identified.
Recently, Ytt-90 radioembolization was also proposed as an alternative to PVE in HCC cirrhotic patients. 17 Our results support these findings because only one patient required PVE before surgery to increase the FLRV/TLV ratio above 30 %. However, in our series, the increase in the FLR/TLV ratio was primarily due to liver tumor shrinkage rather than hypertrophy of the FLRV.
Our series is currently the largest to report on secondarily resected patients with ICC after downstaging with Ytt-90 radioembolization plus systemic chemotherapy, but it has some limitations. First, our downstaging rate of 80 % was biased by our patient's selection criteria; we only considered patients with unique tumor on noncirrhotic liver and without extrahepatic disease, which represents only 10 (22 %) of 45 patients. Second, our population included only eight patients, and the median follow-up time remains limited. Therefore, we cannot yet outline the oncologic interest of the method. However, considering the time from the initiation of chemotherapy, nearly all patients were followed for more than 1 year, and one patient remained alive 3 years after surgery. We intentionally did not compare the survival of the eight resected patients with the 37 remaining patients because these two groups were different (unresected patients had generally multiple hepatic tumors and/or extrahepatic metastases).
In conclusion, our experiences is the largest series that support the notion that Ytt-90 radioembolization plus systemic chemotherapy might be an effective therapeutic option to downstage huge, unique, and initially nonresectable ICCs for secondary resections. Better selection of candidates for surgery, larger numbers of patients, and longer follow-up times are required to further validate this perspective.
